Incompatible kidney transplantation: A brief overview of the past, present and future

QJM: An International Journal of Medicine

Volumn 105, Issue 12, 2012, Pages 1141-1150

  Sharif, A ^a   Alachkar, N ^b   Kraus, E ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BELIMUMAB; BORTEZOMIB; ECULIZUMAB; HLA ANTIGEN; MDX 1342; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BLOOD GROUP ABO SYSTEM; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 84870351036     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs154     Document Type: Review

References (52)

1. Garonzik Wang JM, Montgomery RA, Kucirka LM, Berger JC, Warren DS, Segev DL. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol 2011; 6:2041-6.
2. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocls. Am J Transplant 2010; 10:449-57.
3. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcomes. Clin J Am Soc Neph 2011; 6:922-36.
4. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 meeting report: new concepts in antibodymediated rejection. Am J Transplant 2012; 12:563-70.
5. Gloor J, Stegall M. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010; 6:297-306.
6. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-9.
7. Zachary A, Reinsmoen NL. Antiallograft antibodies: relevance, detection and monitoring. Curr Opin Organ Transplant 2011; 16:410-5.
8. Claas FHJ, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis IIN. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcomes. Transplantation 2004; 78:190-3.
9. Higgins R, Lowe D, Hathaway M, Lam FT, Kashi H, Tan LC, et al. Double filtration plasmapheresis in antibodyincompatible kidney transplantation. Ther Apher Dial 2010; 14:392-9.
10. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11:1359-67.
11. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011; 11:196-202.
12. Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009; 183:6145-509.
13. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-13.
14. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8:492-6.
15. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363:1451-62.
16. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-60.
17. Haas M. The signifcance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 2010; 15:21-7.
18. Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, et al. Subclinical acute antibody-mediated rejection in positive corssmatch renal allografts. Am J Transplant 2007; 7:576-85.
19. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts - lessons from pathology. Clin J Am Soc Nephrol 2006; 1:415-20.
20. Oettl T, Zuliani E, Gaspert A, Hopfer H, Dickenmann M, Fehr T. Transplantation 2010; 89:702-6.
21. Sharif A, Zachary A, Hiller J, Segev D, Alachkar N, Kraus E, et al. Rescue kidney paired donation as emergency salvage for failed desensitization. Transplantation 2012; 93:e27-9.
22. Lawrence L, Galliford JW, Willicombe MK, McLean A, Lesabe M, Rowan F, et al. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011; 92:1129-33.
23. Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, et al. Human leukocyte antigen antibodyincompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92:900-6.
24. Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012; 93:603-9.
25. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318-26.
26. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246-55.
27. Gloor JM, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572-7.
28. Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, et al. The 5-year outcome of ABOincompatible kidney transplantation with rituximab induction. Transplantation 2011; 91:853-7.
29. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigenspecific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85:1745-54.
30. Flint SM, walker RG, Hogan C, Haeusler MN, Robertson A, Francis DMA, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11:1016-24.
31. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10:582-9.
32. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87:268-73.
33. Vo A, Peng A, Totoda M, Kahwaji J, Cao K, Lai CH, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89:1095-102.
34. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9:536-42.
35. Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, et al. Human leukocyte antigen antibody incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxiv crossmatch. Transplantation 2011; 92:900-6.
36. Tobian AA, Shirley RS, Montgomery RA, Cai W, Haas H, Ness PM, et al. ABO antibody titer and risk of antibodymediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10:1247-53.
37. Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao K, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6:2894-900.
38. Baek CH, Yang WS, Park KS, Han DJ, Park JB, Park SK. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra 2012; 2:66-75.
39. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187-98.
40. Sharif A, Alachkar N, Bagnasco S, Geetha D, Gupta G, Womer K, et al. BK virus allograft nephropathy: enhanced risk for ABO- compared to HLA-incompatible kidney transplantation. Clin J Am Soc Nephrol 2012; 7:1320-7.
41. Sinha D, Lambie M, Krishnan N, McSorley K, Hamer R, Lowe D, et al. Cryofiltration in the treatment of cryoglobulinemia and HLA antibody-incompatible transplantation. Ther Apher Dial 2012; 16:91-6.
42. Jordan SC, Kahwaji J, Toyoda M, Vo A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011; 16:416-24.
43. Rose-John S, Waetzig GH, Scheller J, Grö tzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007; 11:613-24.
44. Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dörner T, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011; 63:1255-64.
45. Saidman SL, Duquesnoy RJ, Demetris AJ, McCauley J, Ramos H, Mazariegos G, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2:61-7.
46. Flye MW, Duffy BF, Phelan DL, Ratner LE, Mohanakumar T. Protective effects of liver transplantation on a simultaneously transplanted kidney in a highly sensitized patient. Transplantation 1990; 50:1051-4.
47. Olausson M, Mjörnstedt L, Nordén G, Rydberg L, Mölne J, Bäckman L, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized crossmatch positive recipients. Am J Transplant 2007; 7:130-6.
48. Ingelsten M, Karlsson-Parra A, Granqvist AB, Mölne J, Olausson M, Haraldsson B, Nyström J. Postischemic inflammatory response in an auxiliary liver graft predicts renal graft outcome in sensitized patients. Transplantation 2011; 91:888-94.
49. Eid A, Moore SB, Wiesner RH, DeGoey SR, Nielson A, Krom RA. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990; 50:331-4.
50. Lynch RJ, Platt JL. Accommodation in renal transplantation: unanswered questions. Curr Opin Organ Transplant 2010; 15:481-5.
51. Tanabe T, Ishida H, Horita S, Yamaguchi Y, Toma H, Tanabe K. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol 2011; 25:1-6.
52. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293:1883-90.